Asensus Surgical Inc.

Asensus Surgical, Inc. is a medical device company that offers its products within the United States, Europe, and Asia. The company research, develop, and sell medical device robotics that support minimally invasive surgery. Founded in 2006, Asensus Surgical has its headquarters in Durham, North Carolina. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. The company's products aim to improve the quality of minimally invasive surgery (MIS) through digital laparoscopy. Asensus has developed the first machine vision system for use in robotic surgery. Asensus' products include the Senhance Surgical system, which is a multi-port robotic surgery system that supports up to four arms, which control robotic instruments in addition to a camera. The Senhance Surgical system is also the first robotic surgery system to offer augmented intelligence capabilities. Incisions created with this system are 50% smaller than those created with traditional robotic surgery. Stock for Asensus Surgical, Inc. is listed on the NYSE under the ticker ASXC. In addition to the Senhance Surgical system, Asensus offers the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform, instruments for use with its systems, and the Senhance Ultrasonic System, which delivers controlled energy to ligate and divide tissue. Add Asensus Surgical, Inc. stock to your eToro watchlist to receive news and updates on the ASXC share price.